Skip to main content

Advertisement

SpringerLink
Log in

Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

  • Alzheimer's Disease and Related Disorders - Short Communication
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Growing evidence advanced the idea that the soluble form of the receptor for advanced glycation end-products (sRAGE) might serve as a risk marker for several disorders including Alzheimer disease. We found a reduced level of circulating sRAGE in patients with mild cognitive impairment (MCI). The reduction of sRAGE in MCI, as well as the anticipation of the disease in patients with the lowest sRAGE levels (≤225 pg/ml), suggest a role of the RAGE axis in the pathogenesis of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Arancio O, Zhang HP, Chen X et al (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096–4105

    Article  PubMed  CAS  Google Scholar 

  • Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–886

    Article  PubMed  CAS  Google Scholar 

  • Bucciarelli LG, Wendt T, Rong L et al (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117–1128

    Article  PubMed  CAS  Google Scholar 

  • Emanuele E, D’Angelo A, Tomaino C et al (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62:1734–1736

    Article  PubMed  Google Scholar 

  • Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037

    Article  PubMed  CAS  Google Scholar 

  • Geroldi D, Falcone C, Emanuele E (2006a) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13:1971–1978

    Article  PubMed  CAS  Google Scholar 

  • Geroldi D, Falcone C, Minoretti P et al (2006b) High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54:1149–1150

    Article  PubMed  Google Scholar 

  • Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548

    PubMed  CAS  Google Scholar 

  • Lue LF, Yan SD, Stern DM et al (2005) Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord 4:249–266

    Article  PubMed  CAS  Google Scholar 

  • McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944

    PubMed  CAS  Google Scholar 

  • Petersen RC, Doody R, Kurz A et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308

    Article  PubMed  CAS  Google Scholar 

  • Yan SD, Roher A, Chaney M et al (2000) Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim Biophys Acta 1502:145–157

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants 2004/agreement number 533 F/B/1, “Strategico” 2006, RC 2007 Italian Ministry of Health.

Author information

Authors and Affiliations

  1. NeuroBioGen Lab-Memory Clinic, IRCCS “Centro S. Giovanni di Dio-FBF”, AFaR, via Pilastroni 4, 25125, Brescia, Italy

    R. Ghidoni, L. Benussi, M. Glionna, M. Franzoni & G. Binetti

  2. Interdepartmental Center for Research in Molecular Medicine (CIRMC), University of Pavia, Pavia, Italy

    D. Geroldi & E. Emanuele

Authors
  1. R. Ghidoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Benussi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Glionna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Franzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Geroldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Emanuele
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Binetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Binetti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghidoni, R., Benussi, L., Glionna, M. et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 115, 1047–1050 (2008). https://doi.org/10.1007/s00702-008-0069-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-008-0069-9

Keywords

Search

Navigation